* To evaluate whether STP7 (mavoglurant) treatment alters the subjective effects of cocaine measured by Visual Analog Scales (VAS) and Brief Substance Craving Scale (BSCS). conditions: Cocaine Use Disorder studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 20 type: ESTIMATED name: STP7 (mavoglurant) or Placebo measure: Incidence of Treatment-Emergent Adverse Events. measure: Heart Rate response following the STP7 treatment with the cocaine infusion. measure: Heart Rate response following the STP7 treatment with the cocaine infusion. measure: Blood Pressure (diastolic) response following the STP7 treatment with the cocaine infusion . measure: Blood Pressure (diastolic) response following the STP7 treatment with the cocaine infusion. measure: Blood Pressure (systolic) response following the STP7 treatment with the cocaine infusion. measure: Blood Pressure (systolic) response following the STP7 treatment with the cocaine infusion. measure: ECG changes (HR) following the STP7 treatment with the cocaine infusion. measure: ECG changes (RR) following the STP7 treatment with the cocaine infusion. measure: ECG changes (PR) following the STP7 treatment with the cocaine infusion. measure: ECG changes (QRS) following the STP7 treatment with the cocaine infusion. measure: ECG changes (QT) following the STP7 treatment with the cocaine infusion. measure: ECG changes (HR) following the STP7 treatment with the cocaine infusion. measure: ECG changes (RR) following the STP7 treatment with the cocaine infusion. measure: ECG changes (PR) following the STP7 treatment with the cocaine infusion. measure: ECG changes (QRS) following the STP7 treatment with the cocaine infusion. measure: ECG changes (QT) following the STP7 treatment with the cocaine infusion. measure: Pharmacokinetics: Maximum Plasma Concentration [Cmax] of cocaine. measure: Pharmacokinetics: Maximum Plasma Concentration [Cmax] of benzoylecgonine. measure: Pharmacokinetics: Maximum Plasma Concentration [Cmax] of STP7. measure: Pharmacokinetics: Maximum Plasma Concentration [Cmax] of STP7. measure: Pharmacokinetics: time to maximum plasma concentration [Tmax] of cocaine. measure: Pharmacokinetics: time to maximum plasma concentration [Tmax] of benzoylecgonine. measure: Pharmacokinetics: time to maximum plasma concentration [Tmax] of STP7. measure: Pharmacokinetics: time to maximum plasma concentration [Tmax] of STP7. measure: Pharmacokinetics: area under the concentration-time curve from time 0 to time t of cocaine. measure: Pharmacokinetics: area under the concentration-time curve from time 0 to time t of benzoylecgonine. measure: Pharmacokinetics: area under the concentration-time curve from time 0 to time of STP7. measure: Pharmacokinetics: area under the concentration-time curve from time 0 to time of STP7. measure: Pharmacokinetics: area under the concentration-time curve from time 0 to 12 hours post-dose of cocaine. measure: Pharmacokinetics: area under the concentration-time curve from time 0 to 12 hours post-dose of benzoylecgonine. measure: Pharmacokinetics: area under the concentration-time curve from time 0 to 12 hours post-dose of STP7. measure: Pharmacokinetics: area under the concentration-time curve from time 0 to 12 hours post-dose of STP7. measure: Pharmacokinetics: area under the concentration-time curve from time 0 to time infinity post-dose of cocaine. measure: Pharmacokinetics: area under the concentration-time curve from time 0 to time infinity post-dose of benzoylecgonine. measure: Pharmacokinetics: area under the concentration-time curve from time 0 to time infinity post-dose of STP7. measure: Pharmacokinetics: area under the concentration-time curve from time 0 to time infinity post-dose of STP7. measure: Pharmacokinetics: trough plasma concentration (Ctrough) of cocaine. measure: Pharmacokinetics: trough plasma concentration (Ctrough) of benzoylecgonine. measure: Pharmacokinetics: trough plasma concentration (Ctrough) of STP7. measure: Pharmacokinetics: trough plasma concentration (Ctrough) of STP7. measure: Pharmacokinetics: terminal rate constant of cocaine. measure: Pharmacokinetics: terminal rate constant of benzoylecgonine. measure: Pharmacokinetics: terminal rate constant of STP7. measure: Pharmacokinetics: terminal rate constant of STP7. measure: Pharmacokinetics: half-life of cocaine. measure: Pharmacokinetics: half-life of benzoylecgonine. measure: Pharmacokinetics: half-life of STP7. measure: Pharmacokinetics: half-life of STP7. measure: Pharmacokinetics: clearance of cocaine. measure: Pharmacokinetics: clearance of benzoylecgonine. measure: Pharmacokinetics: clearance of STP7. measure: Pharmacokinetics: clearance of STP7. measure: Pharmacokinetics: Clearance from plasma after oral administration of cocaine. measure: Pharmacokinetics: Clearance of benzoylecgonine from plasma after oral administration (CL/F) of cocaine. measure: Pharmacokinetics: Clearance from plasma after oral administration (CL/F) of STP7. measure: Pharmacokinetics: Clearance from plasma after oral administration (CL/F) of STP7. measure: Visual evaluation of the STP7 on the subjective effects of cocaine at screening measure: Visual evaluation of the STP7 on the subjective effects of cocaine at baseline and during treatment measure: Craving evaluation of the STP7 on the subjective effects of cocaine. sex: ALL minimumAge: 18 Years maximumAge: 59 Years stdAges: ADULT facility: Altasciences Clinical Kansas status: RECRUITING city: Overland Park state: Kansas zip: 66212 country: United States name: Debra Kelsh, MD role: CONTACT lat: 38.98223 lon: -94.67079 hasResults: False